StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Pharmaceutical Sales by Quarter

Pharmaceutical Sales — Eastern Europe / Middle East / Africa share of Pharmaceutical revenue (%) (%)

QuarterlyAnnual

Merck Pharmaceutical Sales: 2.8% in Q2 2026, down 0.4 pts from a year earlier.

Latest, Q2 2026
2.8%
Period ended Jun 30, 2026
Change on a year earlier
-0.4 pts
3.2% in Q2 2025
History
30 quarters
Since Q1 2019
Sources
11
Documents cited below

Where the Q2 2026 figure comes from

“Eastern Europe / Middle East / Africa | || % Pharmaceutical Sales | 2.9 | % | 2.8 | % | 2.8 | % | 3.2 | % | 3.2 | % | 3.2 | % | 2.3 | % | 2.3 | % | 2.7 | %”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Supplemental Table 3c / 3b (Pharmaceutical Geographic Sales).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPharmaceutical Sales — Eastern Europe / Middle East / Africa share of Pharmaceutical revenue (%) (%)Year on yearSource
Q2 2026Jun 30, 20262.8%-0.4 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 20262.9%-0.3 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 20252.3%-0.2 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 20252.3%-0.4 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 20253.2%+0.8 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 20253.2%+0.4 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 20242.5%+0.2 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 20242.7%+0.6 ptsForm 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 20242.4%-0.3 ptsForm 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q1 2024Mar 31, 20242.8%-0.2 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 20232.3%-0.3 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 20232.1%-0.7 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 20232.7%0.0 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q1 2023Mar 31, 20233.0%-0.2 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 20222.6%+0.3 ptsForm 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 20222.8%-0.3 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗

Cite this data

StockData. (2026). Merck Pharmaceutical Sales (%), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/pharma-geo-eemea-share

See every metric in the Merck KPI table. Data updated Oct 26, 2026.